None

Larotrectinib is a targeted anti-cancer drug mainly suitable for cancer patients with TRK (neuroprimitive ectodermal tumor) gene fusion. TRKGene fusion refers to the fusion of the NTRK gene in the body with other genes, resulting in the production of new and abnormal TRK proteins. This gene fusion is relatively common in some cancers, including a variety of tumor types in infants, children and adults.

Larotinib’s indications mainly cover a variety of cancer types, including but not limited to:

1.Children's soft tissue sarcoma (Infantile Fibrosarcoma): This is a common soft tissue tumor in children. TRK gene fusion is more common in this case.

2.Thyroid Cancer (Thyroid Cancer): Some patients with thyroid cancer may develop TRK gene fusion, and larotrectinib can be used to treat such patients.

3.Lung Cancer (Lung Cancer): In some lung cancer patients, especially non-small cell lung cancer (NSCLC) patients, TRK gene fusion may be found.

4.Other cancer types: TRKGene fusion may also appear in some other tumor types, such as pancreatic cancer, colorectal cancer, etc.

Larotrectinib has been launched in China and has not yet been included in medical insurance. Since it has not been launched in China for a long time, it may be difficult to purchase it in hospitals. For specific conditions, it is recommended to consult the local hospital pharmacy. In foreign markets, larotinib has two options: original drug and generic drug. Original drugs include the German version, the American version, the European version and the Hong Kong version, and the price is about 10,000 to 20,000 yuan. In comparison, generic drugs are much cheaper. There are Lao and Bangladeshi versions of generic drugs, and the price is around two to three thousand. It is worth noting that the ingredients of original drugs and generic drugs are basically the same.